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Abstract
Purpose Chronic kidney disease has serious implications
with a high risk for progressive loss of renal function,
increased cardiovascular events as well as a substantial
financial burden. The renin-angiotensin-aldosterone system
(RAAS) is activated in chronic kidney disease, especially in
diabetes and hypertension, which are the leading causes of
chronic kidney disease. Angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers (ARBs)
decrease the rate of progression of diabetic and non-diabetic
nephropathy and are recommended therapy for chronic
kidney disease.
Methods Key clinical trials supporting the use of ACE
inhibitors and ARBs in chronic kidney disease are
discussed. Recent developments in our understanding of
RAAS biology and the use of direct renin inhibition are
reviewed in the context of their potential impact on the
prevention and management of chronic kidney disease.
Results Despite the clinical success of ACE inhibitors and
ARBs the rates of mortality and progression to renal failure
remain high in these patient populations. ACE inhibitor or
ARB monotherapy, in doses commonly used in clinical
practice does not result in complete suppression of the
RAAS. Aliskiren, a direct renin inhibitor, offers a novel
approach to inhibit the RAAS in chronic kidney disease.
Conclusions High dose ARB therapy or combination
therapies with ACE inhibitors and ARBs have shown
beneficial effects on surrogate markers of chronic kidney
disease. Early data based on urinary protein excretion rates
as a surrogate marker for renal function suggest a possibly
novel role for aliskiren alone or in combination with ARBs
in chronic kidney disease.
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Introduction
Chronic kidney disease is defined as kidney damage, as
assessed by biopsy or markers of kidney damage, for
≥3 months with or without changes in glomerular filtration
rate, or a glomerular filtration rate ≤60 ml/min/1.73 m
2 for
≥3 months with or without kidney damage [1]. Chronic
kidney disease is an increasingly prevalent problem that is
debilitating, increases premature morbidity and mortality,
and is very costly to manage. The prevalence of chronic
kidney disease in the United States in 1999–2004 was
estimated to be between 13.1% [2] and 16.8% [3] and will
likely continue to increase given the prevalence of obesity,
diabetes and hypertension, all risk factors for chronic
kidney disease [3].
Chronic kidney disease is a frequent prelude to end stage
renal disease. Patients with end stage disease must receive
renal replacement therapy consisting of either renal trans-
plant or dialysis. Despite these therapies, the 5 year survival
rate for patients with end stage renal disease year is only
38% [4]. End stage renal disease occurs in 0.03% of the US
population, but the management of this disease consumes
nearly 7% of the Medicare budget [5]. As of 2007,
Medicare and non-Medicare costs for end stage renal
disease had reached $20.1 billion and $12.4 billion,
respectively. The most recent estimate suggests annual
Medicare costs of $68,000, $49,000, and $24,000 for
hemodialysis, peritoneal dialysis, and transplant patients,
respectively [5].
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depending on comorbidities, but it is far less expensive than
managing end stage renal disease. In an analysis of over 30
million members across 35 health plans with records from
2000 to 2006, 11,531 patients with diabetes, 74,759 patients
with hypertension, and 4,779 patients with both conditions
were identified [6]. The adjusted annualized incremental all-
cause health care costs associated with chronic kidney disease
were $7,190 in the diabetes cohort, $5,450 in the hyperten-
sion cohort, and $9,177 in the diabetes+hypertension cohort.
So, if chronic kidney disease costs at least $5,000 per year in
all 46 million US patients, that would translate into $230
billion of incremental all-cause health care costs—if all these
patients were members of these health insurance plans.
Chronic kidney disease is associated with an increased
risk of cardiovascular events, death and hospitalizations,
and these risks increase proportionally to kidney functional
decline [7]. The importance of the renin-angiotensin-
aldosterone system (RAAS) in the pathogenesis of chronic
kidney disease is widely appreciated, and this understand-
ing is due largely to the results obtained with pharmaco-
logic agents that block the system. Angiotensin converting
enzyme (ACE) inhibitors and angiotensin receptor blockers
(ARBs) slow the progression of chronic kidney disease[8–
10] and are recommended as first line therapy in the
treatment of this disease [11].
Over the past few years our understanding of the
complexity and pervasive effects of the RAAS has grown as
new components, functions and regulatory steps have been
identified. Moreover, a new drug class, direct renin inhibitors,
has been developed that offers another therapeutic option to
suppress the RAAS in cardiorenal diseases. The focus of this
review is to discuss recent developments in RAAS biology of
potential clinical relevance to chronic kidney disease and the
potential impact of direct renin inhibition on the prevention
and management of chronic kidney disease.
Overview of the renin-angiotensin-aldosterone system
and new developments
The RAAS is a coordinated cascade of sequential enzymatic
steps, the first of which is the release of renin from
juxtaglomerular cells in the kidney. (Fig. 1) Renin is formed
by the proteolytic removal of a 43 amino acid prosegment
peptide from its precursor, prorenin [12]. Renin is stored in
secretory granules and is released in response to decreases in
renal perfusion pressure, decreases in Cl
- in the distal tubule
fluid or increased sympathetic nerve stimulation via β1
adrenoceptors. Renin release can also be inhibited by a direct
action of angiotensin II on the juxtaglomerular cells. Many
other factors are known to modify renin release and/or
expression including vitamin D [13], uric acid [14], TGFβ
[15], and TNFα [16]. Renin acts on circulating angiotensi-
nogen derived from the liver as well as locally produced to
form angiotensin I (Ang I). Ang I is converted to the active
peptide, angiotensin II (Ang II), by membrane bound ACE.
Other active and inactive metabolites can be formed from
Ang I and II by ACE-2, a homologue of ACE. ACE-2 is
expressed in the kidney, heart and other organs and is not
inhibited by ACE inhibitors [17]. ACE-2 generates the
biologically active peptide, Ang (1–7), from Ang II and the
inactive peptide Ang (1–9) from Ang I [17, 18]. Ang (1–7) by
activating its receptor, Mas, has actions that generally opposed
those of Ang II including vasodilation and antiproliferative
effects [17]. In mouse models of diabetic nephropathy ACE-2
is down regulated [19] and knockout of ACE-2 or inhibition
of its activity promotes proteinuria and worsens glomerular
injury in this model [19, 20]. Therefore, during RAAS
activation ACE-2 may counter act the actions of ACE by
forming Ang (1–7) and by breaking down Ang I [17, 18].
Intrarenal renin-angiotensin-aldosterone system
The circulating RAAS is an endocrine system that exerts
primary control over the maintenance of extracellular fluid
volume and (together with the autonomic nervous system)
the regulation of blood pressure. In addition, many tissues,
especially those associated with the cardiovascular system,
contain all or some of the components of the RAAS and
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Fig. 1 The renin-angiotensin-aldosterone system. DRI, direct renin
inhibitor; ACE, angiotensin converting enzyme; ACEI, angiotensin
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based systems can function independently of the traditional
circulating system and are thought to act in a paracrine
manner to regulate organ function, growth and cellular
proliferation, and are involved in pathological events
associated with end organ damage [21]. The kidney
contains all the elements of the RAAS, and intrarenal
formation of Ang II independent of the circulating system
has been amply demonstrated [22].
Angiotensin II
Ang II acts on at least 2 different receptor subtypes, the
type 1 (AT1) and type 2 (AT2) receptors [12]. The AT1
receptor is the predominate receptor in most tissues and
mediates all of the classic physiologic and pathophysiologic
actions of Ang II. In addition to the well known actions of
Ang II to induce vascular smooth muscle contraction,
activate Na
+ transport in the proximal tubule and to
stimulate aldosterone release from the zona glomerulosa
in the adrenal glands, Ang II has been implicated in the
processes of inflammation and endothelial dysfunction,
both of which are associated with hypertension and chronic
kidney disease. For example, Ang II activates NAD(P)H
oxidases and xanthine oxidase producing reactive oxygen
species such as peroxynitrite, superoxide anion and hydro-
gen peroxide, which reduce nitric oxide bioavailability and
contribute to endothelial dysfunction [23]. Ang II also
activates the transcription factor, NF-kB, which induces the
formation of chemokines and cell adhesion molecules that
are involved in the inflammatory process [24]. In addition,
Ang II appears to be an important mediator in the induction
of TGFβ, tissue remodeling, fibrosis, and extracellular
matrix formation, all of which are processes involved in the
pathogenesis of diabetic nephropathy [24] (Fig. 2).
Aldosterone
In addition to its well known actions in promoting Na
+
reabsorption by the kidney, there is now clear evidence that
aldosterone-mediated activation of the mineralocorticoid
receptor in non-epithelial tissues of the heart, kidney, and
vasculature induces fibrotic changes in these tissues [25],
contributes to oxidative stress and vascular inflammation
[26], and is associated with endothelial dysfunction [27].
Prorenin and the (pro)renin receptor
The discovery of the (pro)renin receptor [28] has added
another dimension to the complexity of the RAAS. This
receptor, which is present in many organs including the
heart and kidney, binds both renin and prorenin [29].
Binding of renin to this receptor increases its catalytic
activity. More importantly, prorenin, which is normally
inactive, becomes catalytically active following binding to
this receptor without undergoing proteolysis and thus can
contribute to local Ang II formation [29]. This may be of
particular importance in diseases such as diabetes in which
prorenin is significantly elevated and represents 95% of
circulating renin [30].
Activation of the (pro)renin receptor in mesangial cells
also activates mitogen-activated protein kinase, ERK 1 and
2 and several fibrosis/remodeling mediators such as TGFβ
and PAI-1 [28, 31]. These effects are independent of Ang II
as they occur in the presence of ACE inhibitors or ARBs
[28]. Although more research is needed, activation of the
(pro)renin receptor may contribute to the pathology of renal
disease by increasing local Ang II formation and by
increasing the expression of profibrotic mediators. However,
the in vivo effects of (pro)renin receptor overexpression on
end organ damage in experimental animals are mixed and
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Cardiovasc Drugs Ther (2010) 24:139–149 141therefore the role of this receptor in chronic kidney disease
remains to be determined [32].
Role of the renin-angiotensin-aldosterone system
in chronic kidney disease
Chronic kidney disease is associated with increased
cardiovascular events, premature mortality, decreased qual-
ity of life, and increased health-care expenditures [3].
Diabetes and hypertension are the leading causes of chronic
kidney disease [11] and there is now ample experimental
and clinical evidence showing that the intrarenal RAAS is
activated and plays a critical role in the pathogenesis of
chronic kidney disease [33–36].
Experimental studies
Early studies in experimental models of renal disease led to
the proposal that following renal injury and decrements in
glomerular filtration rate the remaining viable nephrons
undergo structural and functional compensatory changes
which increase glomerular filtration rate sufficiently to meet
excretory demands [37]. Chief among these adaptations is
an increase in glomerular capillary pressure. However, the
increase in glomerular pressure results in injury to
glomerular epithelial and endothelial cells and mesangial
cell expansion. These changes ultimately lead to further
glomerular damage and a vicious cycle of progressive
nephron loss [37]. Ang II is one of the main regulators of
glomerular pressure, and ACE inhibitors, but not other
antihypertensive agents, were found to prevent the rise in
glomerular pressure and to offer protection against protein-
uria and glomerulosclerosis in these animal models [37].
Clinical trials with angiotensin converting enzyme
inhibitors and angiotensin receptor blockers
Based largely on preclinical data in chronic kidney disease
models a number of clinical trials were conducted to assess
the effects of ACE inhibitors and subsequently, ARBs, on
the progression of diabetic and nondiabetic nephropathy.
The first such trial examined the effects of captopril in
patients with type 1 diabetic nephropathy. After a median
follow up of 3 years, patients receiving captopril as
compared to placebo had a 48% reduction in the risk of
doubling of serum creatinine and a 50% reduction in the
combined risk of death, dialysis and transplantation [8]. In
patients with chronic kidney disease of various etiologies,
benazepril resulted in a 53% reduction in the doubling of
serum creatinine or the need for dialysis [38].
Two subsequent studies evaluated the effects of ARBs in
patients with nephropathy associated with type 2 diabetes.
In the Irbesartan Diabetic Nephropathy Trial (IDNT)[9], the
effect of irbesartan on renal and cardiovascular morbidity
and mortality was compared to that of amlodipine and
placebo. For subjects receiving irbesartan treatment, the
relative risk of reaching the primary composite endpoint of
doubling of serum creatinine, end-stage renal disease or
death from any cause was 20% lower than the placebo
group and 23% lower than the amlodipine group. Similarly,
in the Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan study (RENAAL)
[10], losartan reduced the risk of doubling of serum
creatinine, end stage renal disease or death by 16%
compared to the placebo group. While losartan treatment
was associated with a 28% reduction in the risk of end
stage renal disease, there was no effect on the rate of death.
In all these trials the benefits of renin-angiotensin-
aldosterone system blockade on chronic kidney disease
appeared to be beyond those attributable solely to changes
in blood pressure. Based on these results, ACE inhibitors or
ARBs are recommended as first line therapy for chronic
kidney disease [11].
Optimizing renin-angiotensin-aldosterone
system blockade
While it is clear that ACE inhibitors and ARBs reduce the
progression of chronic kidney disease in some patients,
these agents have not been shown to reduce mortality in
this population, and the majority of patients continues to
lose renal function and eventually do progress to end stage
renal disease. There are a number of possible reasons for
this. In early trials such as RENAAL and INDT the
treatment regimens did not reduce blood pressure to today’s
aggressive goals of <130/80 mmHg and in RENAAL 37%
of the patients had no proteinuria reduction at all.
Furthermore, factors such as salt intake can have a major
impact on the progression of chronic kidney disease
especially in the early stages of the disease. Hypertension
in chronic kidney disease is often salt sensitive and changes
in salt intake in the physiologic range can have major
effects on blood pressure and can also attenuate the
therapeutic effectiveness of RAAS inhibition [39].
Polymorphism of the genes encoding for the various
components of the RAAS may also affect the response to
treatment in patients with chronic kidney disease. The best
characterized of these is the insertion (I)/deletion (D)
polymorphism of the ACE gene. Patients carrying the D
allele (DD or DI) have a greater risk of developing diabetic
nephropathy compared with the II genotype [40, 41]. ACE
inhibitor therapy seems to be most effective in patients with
type 1 or type 2 diabetes with the II genotype at earlier
stages of chronic kidney disease [42]. In patients with type
142 Cardiovasc Drugs Ther (2010) 24:139–1492 diabetes and overt albuminuria, ARBs are more effective
in reducing outcomes in patients with the DI or DD
genotype compared to the II genotype [41]. Polymorphisms
in the genes of other components of the RAAS have been
described but their role in kidney disease progression or
effects on treatment regimens are still under investigation
[42].
Other potential reasons for suboptimal clinical outcomes
with ACE inhibitors and ARBs may be associated with
insufficient blockade of the RAAS with currently used
dosing, especially in the setting of an activated intrarenal
system as occurs in diabetes [43]. In up to 50% of patients
chronically treated with ACE inhibitors, Ang II levels
gradually returned to baseline [44]. This phenomenon has
been termed “ACE escape” and is likely due to a
compensatory increase in plasma renin activity due to
disruption of the feedback loop by which Ang II normally
inhibits renin release [12]. Under these circumstances Ang
II can be formed from Ang I by alternative, ACE-
independent pathways, such as chymase, which has been
shown to be upregulated in diabetic and hypertension
related nephropathies [45]. Likewise, ARBs increase
plasma renin activity due to inhibition of the Ang II-renin
release feedback loop [46]. In this case the increase in Ang
II may compete with the ARB for the AT1 receptor [47].
Since renal outcomes appear to be directly related to the
degree of blood pressure and proteinuria reduction [48, 49],
optimizing RAAS blockade with ACE inhibitor/ARB
combination therapy or high dose ARB has been explored
mostly in small groups of patients using proteinuria as a
surrogate maker.
Angiotensin converting enzyme inhibitor/angiotensin
receptor blocker combination therapy
In patients with comorbid type 2 diabetes, microalbuminuria
and hypertension, the combination of candesartan and
lisinopril produced greater reductions in mean sitting diastolic
and systolic blood pressures than did the respective mono-
therapy [50]. The change in the urinary albumin/creatinine
ratio with combination therapy (−50%) was significantly
better than that observed in the candesartan group (−24%)
but was similar to that seen in the lisinopril group (−39%).
The recent analysis of renal outcomes in the large ONTAR-
GET trial [51] found that ramipril/telmisartan combination
therapy decreased proteinuria but worsened the primary renal
composite outcome of dialysis, doubling of serum creatinine
and death when compared to ramipril and telmisartan
monotherapy in patients at high vascular risk. This result
was surprising in that proteinuria is a risk factor in patients
with type 2 diabetic nephropathy and reductions in protein-
uria lead to proportional increases in renal protection [52].
However, this trial was not powered to detect differences in
major renal outcomes [51] and overt proteinuria was present
in only 12.2% of patients with diabetes and in only 4% of all
patients at study entry [51]. Moreover, proteinuria was
measured only at 2 year intervals [51] versus the recom-
mended 2 or 3 times a year [11]. Furthermore, in the
combination therapy group, the rate of decline in estimated
glomerular filtration rate was only slightly above that due to
normal aging [53]. Therefore, while this trial suggests that
telmisartan/ramipril combination therapy has no renal (or
cardiovascular) benefit and may be harmful in patients with
little or no proteinuria, this trial did not address the efficacy
of ACE inhibitor/ARB combination therapy on renal out-
comes in patients with chronic proteinuric kidney disease.
Three trials are currently underway that target this issue.
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
(VALID, NCT00494715) and the VA NEPHRON-D Study
(NCT00555217) [54], are evaluating the ability of ACE
inhibitor/ARB combinations to decrease mortality and the
progression to end stage renal disease in patients with
diabetic nephropathy. The Long-term Impact of RAS
Inhibition on Cardiorenal Outcomes (LIRICO) trial is
evaluating if combined treatment with ACE inhibitors and
ARBs compared with monotherapy is associated with
additional cardiorenal benefits, in subjects with microalbu-
minuria and 1 or more cardiovascular risk factors [55].
High dose angiotensin receptor blocker therapy
Small, short term studies have examined the effects of high
dose ARB treatment on proteinuria in patients with diabetes
and proteinuria. Doses of ARBs at 2 to 4 times the
maximum recommended doses further reduced protein
excretion in these patients with little or no additional
effects on blood pressure [56–58]. These high doses of
ARBs were generally well tolerated and, while serum
potassium levels increased in some patients, rates of
hyperkalemia (K
+ >5.5 mEq/l) were low. However, long-
term renal outcome data are lacking for this potentially
promising treatment regimen.
Aldosterone antagonism
In some patients, ACE inhibitors and ARBs suppress
aldosterone levels only transiently and they slowly return to
baseline levels over the course of weeks. Observational
studies have shown that this phenomenon, known as
“aldosterone breakthrough”, occurs in up to 41% of patients
with diabetic nephropathy treated with an ARB [59]. These
findings, together with the observation that aldosterone
blockade in combination with ACE inhibitors or ARBs
reduces kidney damage in experimental models of renal
disease, have led to a resurgence of interest in the use of
aldosterone antagonists in the treatment of chronic kidney
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teinuria in patients with proteinuric kidney disease who are
already receiving ACE inhibitors or ARBs [61]. Moreover,
pilot studies suggest that adding aldosterone antagonists on a
background therapy of angiotensin converting enzyme
inhibitors or angiotensin receptor blockers may decrease
the rate of loss of kidney function in chronic kidney disease
patients [62]. Well-designed outcome studies are required to
determine whether addition of aldosterone antagonists to
angiotensin converting enzyme inhibitor or angiotensin
receptor blocker therapy is safe, especially as it relates to
potassium homeostasis, and translate into better outcomes in
patients with chronic kidney disease.
Direct renin inhibition
Inhibition of renin activity has long been considered to be
the logical step to interrupt the RAAS as it is the initial and
rate limiting step in the formation of Ang I. Aliskiren, alone
or combined with hydrochlorothiazide or valsartan, is the
first FDA-approved, orally active direct renin inhibitor, a
new class of compounds designed to inhibit the RAAS.
Unlike ACE inhibitors, ARBs and other antihypertensive
agents that cause an increase in plasma renin activity,
aliskiren directly inhibits the catalytic activity of renin, thus
reducing plasma renin activity and, in turn, the production
of Ang II and aldosterone [63]. Moreover, aliskiren can
counteract the increase in plasma renin activity induced by
ACE inhibitors, ARBs, calcium channel blockers and
diuretics [64–67] (Fig. 3). Therefore, direct renin inhibitors
have the potential of more comprehensive suppression of
the RAAS than ACE inhibitors and ARBs.
Results from several clinical studies support this con-
tention. For example, studies in healthy volunteers [68, 69]
and in patients[70] have shown that aliskiren decreases
elements of the RAAS (Ang II, plasma renin activity and
aldosterone) to a greater extent than ARBs. Moreover, in
volunteers, maximum doses of aliskiren increased renal
blood flow 2-fold greater than maximum doses of ACE
inhibitors and 40% greater than ARBs [71]. In a number of
trials aliskiren has been shown to produce marked
reductions in aldosterone. For example, in the Aliskiren in
the Evaluation of Proteinuria in Diabetes (AVOID) trial
aliskiren when combined with losartan reduced urinary
aldosterone by 24% after 6 months compared with a 4%
decrease with losartan alone [72]. Likewise, in the Aliskiren
in Left Ventricular Hypertrophy (ALLAY) study plasma
aldosterone was reduced by 21% from baseline with
aliskiren/losartan combination therapy, compared with a
5% increase with losartan alone 9 months after the start of
therapy [72]. Finally, in patients with symptomatic heart
failure, aliskiren when combined with optimal therapy
(ACE inhibitor or ARB and beta blocker) reduced urinary
aldosterone by 19% compared with an increase of 2% with
placebo [73]. Combined, these results suggest that aliskiren
may provide more comprehensive suppression of the
circulating and intrarenal RAAS than ACE inhibitors or
ARBs [30].
Experimental studies have shown that aliskiren has the
potential to reduce end organ damage in chronic kidney
disease. For example, in animal models of hypertension and
heart and kidney damage, aliskiren reduced mortality,
proteinuria and end organ damage [74–77]. Importantly,
another study showed that aliskiren extensively partitioned
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144 Cardiovasc Drugs Ther (2010) 24:139–149to the kidney [76]. This fact may explain the marked and
long lasting aliskiren-induced increases in renal blood flow
observed in normal volunteers [71], as well as the persistent
blood pressure-lowering effects of aliskiren in hypertensive
patients following drug withdrawal [78–80].
The mechanisms of renoprotection observed in preclin-
ical studies with aliskiren are still under investigation.
However, in addition to inhibiting the formation of Ang I
by the circulating and intrarenal RAAS [77], aliskiren has
also been shown to reduce the renal expression of the (pro)
renin receptor in an animal model of diabetes [76]. Thus,
aliskiren may contribute to end organ protection by
reducing the deleterious actions of Ang II and the Ang II-
independent effects of (pro)renin receptor activation.
In clinical studies, aliskiren has been shown to be an
effective and long-acting antihypertensive agent when used
alone [79–81] or in combination with other antihyperten-
sive drugs [64–67]. Thus far, 3 studies have evaluated it as
a potential renoprotective agent in chronic kidney disease,
using proteinuria as a surrogate marker. In a small
exploratory study designed to investigate the time course
of aliskiren treatment, patients with type 2 diabetes and
micro- or macroalbuminuria recieved aliskiren and furose-
mide but no other RAAS blockers [78]. Mean 24 h systolic
blood pressure but not diastolic blood pressure was reduced
by 6 mmHg at treatment end (28 days). The urinary
albumin creatinine ratio progressively decreased from
baseline with treatment and a maximum reduction of 44%
was obtained the end of the treatment period. Urinary
albumin creatinine ratio remained below baseline for
approximately 12 days following washout. Compared to
baseline, plasma renin activity was reduced by 68% and
Ang II by 42% at the end of treatment. After aliskiren
withdrawal plasma renin activity and Ang II remained
below baseline for 1 week and gradually returned to
pretreatment levels by 4 weeks.
In a larger study, the Aliskiren in the Evaluation of
Proteinuria in Diabetes (AVOID) trial [82], the effects of
dual blockade of the RAAS with aliskiren plus losartan
were evaluated in patients with comorbid hypertension and
type 2 diabetes with nephropathy. Patients who were
maintained on losartan (100 mg daily) for the duration of
the study were randomized to receive aliskiren (150 mg/d
for 3 mo, then 300 mg/d for 3 mo) or placebo. Three
months of treatment with the combination of aliskiren/
losartan (150/100 mg/d), reduced the urinary albumin
creatinine ratio by 11% compared with losartan alone.
Increasing the dose of aliskiren to 300 mg/d further
decreased albumin excretion to 20% by the end of the
study. Urinary aldosterone was reduced from baseline by
24% in the aliskiren/losartan group versus those patients
receiving losartan alone (−4%) [72]. The reduction in
proteinuria occurred in the absence of significant changes
in blood pressure suggesting that addition of aliskiren to
losartan had potential renoprotective effects independent of
blood pressure. The rates of adverse events or discontinua-
tions between the 2 groups were similar. Hyperkalemia was
reported in 5.0% and 5.7% of patients in the aliskiren and
placebo groups, respectively.
The potential renoprotective effects of aliskiren were
further examined in an exploratory study of the antiprotei-
nuric effects of 300 mg aliskiren compared to, and in
combination with, 300 mg irbesartan, or placebo in a
double blind, randomized cross-over trial [70]. Patients
with type 2 diabetes, hypertension and albuminuria
(>100 mg/day) underwent a 1-month washout period with
no antihypertensive medications, but received furosemide
to prevent blood pressure elevation. Following this, they
were randomly assigned to receive each of the 4 treatments
(aliskiren 300 mg, irbesartan 300 mg, placebo or combina-
tion aliskiren+irbesartan using identical doses) for
2 months. Aliskiren was as efficient as irbesartan in
reducing the urinary albumin excretion rate: 48% and
58%, respectively (P<0.001 vs placebo for both treatments;
P=ns between treatments) [70]. The urinary albumin
excretion rate was reduced with the combination by 71%
(P<0.001 vs placebo), which was significantly greater than
that seen with aliskiren (P<0.001) or irbesartan (P=0.028)
monotherapy. The added antiproteinuric effect with combi-
nation treatment compared with aliskiren alone was about
31%. This additional decrease in proteinuria with the
combination therapy was directly and proportionately
correlated with an increase in plasma renin concentration,
supporting the concept of increased intrarenal RAAS
suppression by aliskiren. The patients enrolled in this small
study had a lower mean baseline UAER compared with that
in the AVOID trial. In contrast to the AVOID study, which
reported an additive antiproteinuric effect with aliskiren
added to a maximal recommended dose of losartan and
optimal antihypertensive therapy, this study directly com-
pared the antiproteinuric effects of aliskiren monotherapy
with ARB monotherapy in addition to confirming the
additive effects seen with the combination [70].
These 3 studies demonstrate that aliskiren alone or
combined with an ARB reduced albumin excretion in
patients with diabetic nephropathy, suggesting that direct
renin inhibition may be an additional treatment option in
patients with type 2 diabetes and nephropathy. While these
initial results are promising, larger long-term trials that
measure cardiovascular and renal outcomes such as
progression to end stage renal disease and cardiovascular
mortality are needed to explore the potential beneficial
effects of direct renin inhibition on chronic kidney disease.
Such trials are ongoing, which will determine whether
aliskiren in combination with an ACE inhibitor or an ARB
reduces endpoints of cardiorenal morbidity and mortality in
Cardiovasc Drugs Ther (2010) 24:139–149 145high risk patients with type 2 diabetes (ALTITUDE) [83]o r
whether aliskiren added to standard therapy reduces
mortality and hospitilizations in patients with heart failure
(ATMOSPHERE, NCT00853658).
Safety and tolerability
In a pooled analysis of data from over 7000 patients with
hypertension treated with aliskiren for 6 to 8 weeks, the
overall incidence of adverse events (AEs, 39.8%) was
similar to placebo (40.2%) [84]. More than 95% of the AEs
were mild or moderate with headache, nasopharyngitis,
diarrhea, and dizziness being the most commonly reported.
The incidence of hyperkalemia (potassium >5.5 mmol/L)
with aliskiren treatment (150 mg, 0.7%; 300 mg, 1.0%) was
similar to placebo (0.6%) Combination of aliskiren (150 mg
or 300 mg) with ramipril, amlodipine, valsartan or
hydrochlorothiazide (HCTZ) resulted in an AE profile
similar to that of the respective monotherapy. However,
the rate of cough was lower with ramipril/aliskiren therapy
(1.8%) compared with ramipril alone (4.7%). Likewise the
rate of edema was lower with aliskiren/amlodipine therapy
(2.1%) compared with amlodipine alone (11.2%) [84].
Rates of hyperkalemia were low and similar to the
respective monotherapy when aliskiren was combined with
amlodipine, valsartan, or HCTZ. However, hyperkalemia
was higher in patients receiving aliskiren/ramipril (5.5%)
compared with ramipril alone (2.6%). In a longer term
(6 months) study of patients with hypertension receiving
aliskiren/valsartan or aliskiren/valsartan/HCTZ, the most
frequent AEs were headache, nasopharyngitis, diarrhea, and
dizziness [85]. Hyperkalemia was reported in 2.0% of
patients and was transient.
In the 2 short-term studies that evaluated the effects of
aliskiren in patients with diabetic nephropathy, no
hyperkalemia was observed [70, 78]. In the longer term
AVOID trial [82] there was no difference in the overall
incidence of AEs between patients recieving losartan
alone (67.1%) versus the losartan/alsikiren group
(66.8%). Likewise the rates of hyperkalemia (5.7% vs
5.0%) were similar between the groups. In the losartan/
alsikiren group 14 patients (4.7%) experienced potassium
levels ≥6.0 mmol/L versus 5 (1.7%) in the losartan group.
However, 9 of the 14 patients treated with losartan/
aliskiren had elevated baseline potassium and should have
been excluded from the study. These studies suggest that
the AEs associated with aliskiren alone or in combination
with ARBs are generally mild and similar to current
therapies. However, as with ACE inhibitors and ARBs,
serum electrolyte levels including potassium need to be
monitored in patients with impaired renal function when
using aliskiren [86].
Summary and conclusions
Chronic kidney disease is a major healthcare problem that will
likely continue to increase due to the ageing population and the
elevated prevalence of hypertension, diabetes and obesity. The
RAAS is activated in chronic kidney disease and pharmaco-
logical modulation of this system has become a cornerstone in
the treatment of this disease. While ACE inhibitors and ARBs
have been shown to retard the progression of chronic kidney
disease, the majority of patients still progress to end stage
disease or die from cardiovascular events. There is a vast need
for further improvement in the therapy of patients with chronic
kidney disease.
Current evidence suggests that inhibition of the RAAS with
ACE inhibitors and ARBs stimulates a compensatory increase
in plasma renin activity that may negate some of the beneficial
effects of these agents. Therefore, strategies that more fully
suppress the RAAS in chronic kidney disease are being
explored. High dose ARB therapy or combination therapies
with ACE inhibitors and ARBs have shown beneficial effects
on surrogate markers of chronic kidney disease. Direct renin
inhibition with aliskiren represents a novel and potentially
moreeffectivewaytoinhibittheRAAS.UnlikeACEinhibitors
and ARBs, plasma renin activity is inhibited with aliskiren, and
downstream components of the RAAS are suppressed. Like
ACE inhibitors and ARBs, aliskiren, alone or in combination
with an ARB, has been shown to reduce proteinuria in patients
with diabetic nephropathy. However, whether these new
treatment regimens confer better outcomes in patients with
chronic kidney disease await the results from ongoing clinical
trials with appropriate endpoints.
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